OREX Orexigen Therapeutics, Inc.

+0.07  (2%)
Previous Close 2.87
Open 2.94
Price To book 0.00
Market Cap 44.77M
Shares 15,227,000
Volume 44,476
Short Ratio 10.41
Av. Daily Volume 229,683

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved September 11 2014. CV outcomes trial terminated May 2015. New safety trial CONVENE initiated 2016. Due to be completed January 2022.

Latest News

  1. 5 Reasons Why VIVUS (VVUS) Stock Should Be in Your Portfolio
  2. The 3 Best Obesity-Drug Stocks to Buy in 2017
  3. Orexigen (OREX) Obesity Drug Contrave Registers Slow Growth
  4. Orexigen Announces Activities at European Congress on Obesity 2017
  5. Edited Transcript of OREX earnings conference call or presentation 9-May-17 9:00pm GMT
  6. Orexigen Posts Wider-than-Expected Loss in Q1, Sales Up Y/Y
  7. Orexigen reports 1Q loss
  8. Orexigen Therapeutics Reports Financial Results for the First Quarter Ended March 31, 2017
  9. Investor Network: Orexigen Therapeutics, Inc. to Host Earnings Call
  10. Orexigen Therapeutics to Provide Business Update at the 2017 Bank of America Merrill Lynch Healthcare Conference
  11. ETFs with exposure to Orexigen Therapeutics, Inc. : May 2, 2017
  12. Navamedic ASA: Enters into partnership agreement with Orexigen Therapeutics for Nordic launch of Mysimba®
  13. Orexigen Therapeutics Announces Commercialization and Distributorship Arrangement with Navamedic ASA for Mysimba® (naltrexone HCl / bupropion HCl prolonged release) in Five Nordic Countries
  14. Today's Research Reports on Stocks to Watch: GrubHub and Orexigen Therapeutics
  15. Orexigen Therapeutics to Provide Business Update and Discuss First Quarter 2017 Financial Results on May 9, 2017
  16. Orexigen Therapeutics Announces New Drug Submission for Contrave© in Canada
  17. ETFs with exposure to Orexigen Therapeutics, Inc. : April 17, 2017
  18. SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Orexigen Therapeutics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
  19. Orexigen Therapeutics, Inc. :OREX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 31, 2017